Giroctocogene fitelparvovec, formerly known as SB-525 or PF-07055480, is a gene therapy being developed to reduce the risk of bleeding episodes in people with hemophilia A.

Albumin fusion is a molecular technology that has been used to create replacement therapies for hemophilia with an extended half-life — treatments that are more long-lasting in the body and can therefore be administered less frequently.

CRISPR/Cas9 is a gene-editing technology that can be used to alter the genetic sequence of a specific gene inside a cell. Several preclinical studies have indicated that the molecular tools in CRISPR/Cas9 might be used to treat or even cure hemophilia.

Although hemophilia, a bleeding disorder that interferes with blood clotting, is more common in men, women can have it, too.

One of the main hemophilia symptoms is excessive bleeding, which can occur into the joints. This type of bleeding can lead to joint damage, or joint arthropathy. Joint damage can limit movement and the ability to exercise for people living with this bleeding disorder.

Hemophilia joint health care involves treatments, physiotherapy, and lifestyle adjustments such as doing low-impact exercises, following a well-balanced nutrition plan, and maintaining good mental health.